Neuralink Secures $650 Million in Funding to Advance Brain-Computer Interface and AI Integration

Tesla(TSLA.US) Neuralink, the brain-computer interface startup founded by CEO Elon Musk, announced on Monday that it has completed a $650 million funding round. The round saw participation from prominent investment firms including ARK Invest, Founders Fund, Sequoia Capital, Thrive Capital, and Lightspeed Venture Partners.

Neuralink stated that the funding will be used to extend the benefits of its technology to more patients and to develop new devices that “further deepen the connection between biological intelligence and artificial intelligence.” The company is dedicated to building brain-computer interface (BCI) systems, which enable direct human control of external technologies by reading brain signals.

Its first product, named “Telepathy,” features a system with 64 threads thinner than a human hair, implanted directly into the brain to record neural signals via 1,024 electrodes. According to the official website, the initial goal of this technology is to help patients with severe paralysis regain a degree of autonomy.

To date, five patients have completed the implantation surgery, enabling them to “control digital or physical devices with their thoughts.”

Neuralink is currently advancing four concurrent clinical trials centered on its Telepathy system to further validate its feasibility and safety.

Brain-computer interfaces are not a concept exclusive to Neuralink; the academic community has been researching this technology for decades. In addition to Neuralink, several other companies, including Synchron, Paradromics, and Precision Neuroscience, are also actively developing similar technologies.

Paradromics also announced on Monday that it had successfully implanted its brain-computer interface system into a human for the first time, marking a further intensification of the competitive landscape.

Although Neuralink has not yet disclosed the specific development direction of its next device, Musk has always held grand visions for the company. He has publicly stated that he is willing to try implanting a Neuralink device.

Restoring vision in the blind is one of the key objectives he has repeatedly emphasized. Neuralink’s device under development, “Blindsight,” has received the “Breakthrough Device” designation from the U.S. Food and Drug Administration. This designation applies to innovative medical devices that hold promise for improving the treatment of life-threatening or irreversibly debilitating diseases.

Elon Musk once posted on X, the social media platform he founded, that Blindsight holds promise for helping patients who have lost both their eyes and optic nerves to “see again.”

Despite Neuralink’s significant recent progress and substantial funding, brain-computer interface (BCI) technology still has a long way to go before achieving true commercialization. From clinical trials to widespread adoption, factors such as technological safety, ethical controversies, regulatory scrutiny, and user acceptance represent numerous hurdles that Neuralink must overcome.

Responsible Editor: Yu Jian SF069